Ews have assessed research in sophisticated thyroid cancer30 and RAIrefractory DTC.22 We also did a PubMed literature search on 19 December 2013, utilizing the terms “clinical trial, phase ii” [Publication Type] AND “thyroid neoplasms” [MeSH Terms] (no date restriction). This yielded 50 reports, of which only ten reported phase 2 research of antiangiogenic agents in DTC. A related look for phase three studies (“clinical trial, phase iii” [Publication Type]) yielded no results in DTC except for the present study style.25 Interpretation Previously, only phase two research of antiangiogenic agents have been reported in RAIrefractory DTC: axitinib,15 motesanib,21 pazopanib,13 sunitinib,14 vandetanib,19 and sorafenib.12,168,20 Hence, data within this setting are limited, and the present phase 3 randomized study demonstrating considerably improved PFS with sorafenib versus placebo offers useful clinical proof. These final results recommend that sorafenib represents a brand new treatment solution for patients with progressive RAIrefractory DTC.6-Bromo-2-oxaspiro[3.3]heptane site Supplementary MaterialRefer to Web version on PubMed Central for supplementary material.Azido-PEG8-acid In stock AcknowledgementsThe authors thank the sufferers, their caregivers, as well as the investigators who participated in this study; the principal investigators are listed in Supplementary Appendix A.PMID:33676903 We also thank Emma Robinson (7.four Restricted, Oxford, UK), who provided health-related writing help funded by Bayer HealthCare Pharmaceuticals. This study was supported by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary. Funding This function was funded by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary. Conflicts of interest MSB has received consultancy fees/honorarium and research assistance from Bayer HealthCare Pharmaceuticals; consultancy costs and analysis assistance from Exelixis; consultancy costs from Onyx Pharmaceuticals; and study help from Eisai, Novartis, and Roche/Genentech. CMN, RP, and YKS have received investigation support from Bayer HealthCare Pharmaceuticals. BJ has received honorarium and analysis support from Bayer HealthCare Pharmaceuticals; consultancy fees/ honorarium from AstraZeneca and Sobi; and honorarium from Eisai, Ipsen, Novartis, OxiGene, Pfizer, Roche, and Sanofi. RE has received consultancy fees/honorarium and research assistance from Bayer HealthCare Pharmaceuticals; and consultancy fees/honorarium from AstraZeneca and Genzyme. SS has received consultancy charges and analysis assistance from Bayer HealthCare Pharmaceuticals; and consultancy charges from Amgen, Celgene, Genomic Wellness, Roche, and Sanofi Aventis.Lancet. Author manuscript; accessible in PMC 2015 March 19.Brose et al.Web page 10 LB has received consultancy fees and investigation help from Bayer HealthCare Pharmaceuticals; and consultancy charges from AstraZeneca. CF has received consultancy fees/honorarium and analysis assistance from Bayer HealthCare Pharmaceuticals; consultancy fees from AstraZeneca, SanofiAventis, and Sobi; in addition to a grant from Roche. FP has received honorarium and study support from Bayer HealthCare Pharmaceuticals. SIS has received study help from Bayer HealthCare Pharmaceuticals; consultancy fees/honorarium and investigation support from Amgen; consultancy fees/honorarium from AstraZeneca, Eisai, Exelixis, Lilly, NovoNordisk, and Veracyte; analysis support from Genzyme and Pfizer; and consultancy fees/honorarium from Onyx and Roche. JWAS has received honorarium and study help from Bayer HealthCare Phar.